Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2008
09/30/2008US7429460 for treating Gaucher's disease by preventing accumulation of phosphatidylcholine (PC), wherein PC accumulation is increased due to the activation of CTP:phosphocholine cytidylyltransferase (CCT) upon glucosylceramide (GlcCer) accumulation
09/30/2008US7429394 Core comprising a potassium binding polymer, shell component comprising a crosslinked amine functional polymer alkylated with hydrophobic agent(s); treatment of phosphate imbalance disorders, hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency
09/30/2008US7429393 Process for forming centipede polymer gels
09/30/2008US7429387 Administering neurotoxin
09/30/2008US7429375 Proteoglycan degrading mutants for the treatment of CNS
09/30/2008CA2626514A1 Sinus relief composition and method of producing the same
09/30/2008CA2505933C Use of botulinum toxin for treating urinary incontinence
09/30/2008CA2488300C Combination of voriconazole and an antifungal cyp2c19 inhibitor
09/30/2008CA2453646C 5-cnac as oral delivery agent for parathyroid hormone fragments
09/30/2008CA2450772C Composition for epigallocatechin gallate
09/30/2008CA2417417C Method for recovery of copper from sulfidic ore materials using super-fine grinding and medium temperature pressure leaching
09/30/2008CA2382480C Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
09/30/2008CA2377762C Sulfonamidomethyl phosphonate inhibitors of .beta.-lactamase
09/30/2008CA2371031C Compositions for treatment of disorders of the oesophagus
09/30/2008CA2355470C Benzoheterocycles and their use as mek inhibitors
09/30/2008CA2338220C Substituted imidazoles having cytokine inhibitory activity
09/30/2008CA2323363C Novel compositions of eprosartan
09/30/2008CA2314009C Triazole and imidazole derivatives
09/30/2008CA2303848C Substituted anilides
09/30/2008CA2297834C Chromium/biotin treatment of type ii diabetes
09/30/2008CA2285573C A method for stimulating red blood cell production
09/30/2008CA2274076C Crystalline form of s-omeprazole
09/30/2008CA2263425C Pharmaceutical agent containing rho kinase inhibitor
09/30/2008CA2261987C Vectors for inhibiting hiv and tumor growth
09/30/2008CA2222811C Stabilized solid dispersions of misoprostol
09/30/2008CA2221096C Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
09/30/2008CA2214219C Pyrido[2,3-d]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
09/30/2008CA2195856C Substituted o6-benzylguanines and use thereof
09/30/2008CA2183050C Sulfonyl- or sulfinylbenzoylguanidine derivatives
09/28/2008CA2627529A1 Fluorinated derivatives of deferiprone
09/25/2008WO2008116226A2 Magnesium compositions and uses thereof
09/25/2008WO2008116215A2 Phosphorus binder for treatment of renal disease
09/25/2008WO2008116195A2 Compositions comprising an sglt2 ingibitor for treating obesity
09/25/2008WO2008116194A2 Blockers of pore-forming virulence factors and their use as anti-infectives
09/25/2008WO2008116185A2 Substituted pyrimidines as adenosine receptor antagonists
09/25/2008WO2008116179A1 Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate
09/25/2008WO2008116163A1 Therapeutic drug combinations for treatment of b-cell malignancies
09/25/2008WO2008116161A2 Pyrazoloanthrone and derivatives thereof for the treatment of cancer expressing 'mullerian inhibiting substance' type ii receptor (misrii) and of excess androgen states
09/25/2008WO2008116158A1 Supramolecular complexes as photocatalysts for reduction of substrates
09/25/2008WO2008116156A2 Methods and compositions for treating diseases and conditions associated with mitochondrial function
09/25/2008WO2008116145A2 Soluble epoxide hydrolase inhibitors
09/25/2008WO2008116144A1 Methods of treating mood disorders
09/25/2008WO2008116141A1 Allylqxy and alkyloxy benzoic acid delivery agents
09/25/2008WO2008116135A2 Topical formulations having enhanced bioavailability
09/25/2008WO2008116133A1 Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture
09/25/2008WO2008116129A2 Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
09/25/2008WO2008116100A1 Methods of suppressing ltp inhibition
09/25/2008WO2008116092A1 Compositions and methods for the diagnosis, treatment, and prevention of amyotrophic lateral sclerosis and related neurological diseases
09/25/2008WO2008116083A1 Use of ranolazine for elevated brain-type natriuretic peptide
09/25/2008WO2008116064A2 Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
09/25/2008WO2008116054A1 Inhibitors of fibroblast activation protein, and methods of use thereof
09/25/2008WO2008116032A1 Compositions and methods for inhibiting tumor cell growth
09/25/2008WO2008116029A1 Modulation of bacterial quorum sensing with synthetic ligands
09/25/2008WO2008115999A1 Biaryl and biheteroaryl compounds useful in treating iron disorders
09/25/2008WO2008115990A1 Methods of preparation and resolution of e/z isomers of vinylfuro[2,3-d] pyrimidine and their biological activities and related compositions and methods of treatment
09/25/2008WO2008115951A1 Fluoroquinolones for treating, reducing, ameliorating, or preventing infections caused by antibacterial drug-resistant bacteria
09/25/2008WO2008115920A2 Methods for the preparation and formulation of l-carnitine valproate salts
09/25/2008WO2008115919A2 Methods for the preparation, formulation and use of lithium valproate
09/25/2008WO2008115915A2 Non-hygroscopic l-carnitine salts
09/25/2008WO2008115894A1 Benzofuran-derived hiv protease inhibitors
09/25/2008WO2008115870A2 Induction and/or maintenance of tumor dormancy by disruption of urokinase plasminogen activator receptor-integrin interaction
09/25/2008WO2008115805A2 Cobalamin taxane bioconjugates
09/25/2008WO2008115797A1 Therapeutic compositions and methods
09/25/2008WO2008115742A1 Chemical compounds
09/25/2008WO2008115723A1 Composition for treating diabetes and metabolic disorders with quercetin, myrcetin and chlorogenic acid
09/25/2008WO2008115706A1 Methods and compositions for treatment of drug addiction
09/25/2008WO2008115705A2 Hexahydro-cycloheptapyrazole cannabinoid modulators
09/25/2008WO2008115672A1 Method for treating cb2 receptor mediated pain
09/25/2008WO2008115671A1 Method for treating cb2 receptor mediated pain
09/25/2008WO2008115656A1 Novel burn treatment composition
09/25/2008WO2008115593A1 1-[(2'-substituted)-piperazin-1'-yl]-isoquinolines as norepinephrine transporter inhibitor therapeutics and positron emission tomography imaging agents
09/25/2008WO2008115572A1 Methods and compositions of nsaids
09/25/2008WO2008115556A2 Identification of genetic alterations that modulate drug sensitivity in cancer treatments
09/25/2008WO2008115531A1 Prevention and treatment of infectious conditions with active vitamin d compounds or mimics thereof
09/25/2008WO2008115529A1 Compositions comprising omega-3 fatty acids and cetp inhibitors
09/25/2008WO2008115525A2 Metal-binding therapeutic peptides
09/25/2008WO2008115499A1 Mannich base n-oxide drugs
09/25/2008WO2008115442A1 Inhibitors of cholesterol ester transfer protein
09/25/2008WO2008115441A1 Use of glucocorticoids for treatment of congestive heart failure
09/25/2008WO2008115433A1 Desferrithiocin polyether analogues
09/25/2008WO2008115413A1 Aromatase inhibitors for the treatment of mastalgia
09/25/2008WO2008115385A2 Piperazine-substituted pyridazinone derivatives useful as glucan synthase inhibitors
09/25/2008WO2008115381A1 Pyridazinone derivatives useful as glucan synthase inhibitors
09/25/2008WO2008115369A2 Inhibitors of focal adhesion kinase
09/25/2008WO2008115281A2 Compounds for treating viral infections
09/25/2008WO2008115263A2 Raf kinase inhibitors containing a zinc binding moiety
09/25/2008WO2008115262A2 Hsp90 inhibitors containing a zinc binding moiety
09/25/2008WO2008115259A2 Derivatives of benzoxadiazole suitable for the treatment of cell proliferative diseases
09/25/2008WO2008115225A2 Methods and compositions for treating fish diseases
09/25/2008WO2008115141A1 4, 5-dihydro-1,3-thiazol-2-amine derivatives and their use in the treatment of respiratory, cardiovascular, neurological or gastrointestinal disorders
09/25/2008WO2008115140A1 Quinoline derivatives, pharmaceutical compositions comprising them, and their use in treating central nervous system and peripheral diseases
09/25/2008WO2008115139A1 A composition comprising (r)-spiro[l- azabicyclo[2.2.2]octane-3,2'(3'h) -furo[2,3 -b]pyridine (azd0328) and its use in the treatment of alzheimer's disease, adhd or cognitive dysfunction
09/25/2008WO2008115118A1 Method and means for preventing and inhibiting type iii secretion in infections caused by gram-negative bacteria
09/25/2008WO2008115098A2 Substituted 2,3,4,5-tetrahydro-1h-pyrido[4,3-b]indoles, methods for the production and the use thereof
09/25/2008WO2008115088A1 Use of rhodamine 6g in the form of a medicinal agent for treating malignant neoplasms and amiloidoses
09/25/2008WO2008114971A1 Novel benzamide derivatives and process for the preparation thereof
09/25/2008WO2008114861A1 Alcohol-containing quinolone pharmaceutical composition
09/25/2008WO2008114859A1 Pharmaceutical composition containing pyrazole derivative
09/25/2008WO2008114857A1 Method for producing aminoacetylpyrrolidinecarbonitrile derivative
09/25/2008WO2008114831A1 Antibacterial agent having sulfonamide group